Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years

Background. Mass vaccination campaigns of the population aged 1–29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Diallo, Aldiouma, Sow, Samba O., Idoko, Olubukola T., Hirve, Siddhivinayak, Findlow, Helen, Preziosi, Marie-Pierre, Elie, Cheryl, Kulkarni, Prasad S., Parulekar, Varsha, Diarra, Bou, Cheick Haidara, Fadima, Diallo, Fatoumata, Tapia, Milagritos, Akinsola, Adebayo K., Adegbola, Richard A., Bavdekar, Ashish, Juvekar, Sanjay, Chaumont, Julie, Martellet, Lionel, Marchetti, Elisa, LaForce, Marc F., Plikaytis, Brian D., Enwere, Godwin C., Tang, Yuxiao, Borrow, Ray, Carlone, George, Viviani, Simonetta
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639491/
https://ncbi.nlm.nih.gov/pubmed/26553684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ518
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados